These animals were also subjected to the same environmental conditions and treatment protocols for a chronic 28-day administration study [2]
Metabolism and Excretion Metabolism AOD 9604 is partially degraded by protease in adipose tissue, generating inactive metabolites
Certificates of Analysis report qualitative identity and percent purity by UV-Vis, quantitative assay, heavy metals by ICP-MS, and total aerobic microbial (TAMC) and total yeast and mold (TYMC) counts
Molecular Basis of Local Action The local effect of AOD 9604 injection is closely related to its molecular properties: Receptor specificity AOD 9604 has a high affinity for 3-AR and reduces systemic side effects
Common Side Effects When side effects occurred, they were typically mild, transient, and similar in frequency to placebo groups: Reported Adverse Effects Most Common (occurring in small percentage of participants): Mild to moderate headaches (most frequently reported, often resolving with continued use) Injection site reactions (minor redness, swelling, or irritation at injection site) Gastrointestinal effects (particularly at higher oral doses: mild nausea, diarrhea, flatulence) Fatigue (reported occasionally during initial adaptation period) Rare Events: One case of chest tightness was deemed possibly related to treatment in safety trials
Once imbalanced, it can lead to decreased bone mass, osteoporosis, and increased risk of fractures